Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Benton

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
American Journal of Hematology|May 2, 2020
Thirty-three years later: Two distinct cases of acute lymphoblastic leukemia in one patientMarisa J L Aitken, Christopher B Benton, Feng Wang, et al.
Leukemia|July 29, 2017
Influence of IDH on FLT3-ITD status in newly diagnosed AMLP Boddu, K Takahashi, N Pemmaraju, et al.
Acta Haematologica|May 22, 2019
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell TransplantationZhihong Zeng, Wenbin Liu, Christopher B Benton, et al.
Annals of Tropical Medicine and Parasitology|June 26, 2002
APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis ControlM Homeida, E Braide, E Elhassan, et al.
The Journal of Investigative Dermatology|March 12, 2002
PARP determines the mode of cell death in skin fibroblasts, but not keratinocytes, exposed to sulfur mustardD S Rosenthal, C M Simbulan-Rosenthal, W F Liu, et al.
Leukemia & Lymphoma|September 17, 2013
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutationsChristopher B Benton, Farhad Ravandi, Michael Andreeff, et al.
Biochimica Et Biophysica Acta|December 26, 2015
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cellsPeter P Ruvolo, Vivian R Ruvolo, Christopher B Benton, et al.
Urology|December 22, 1999
Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniquesF A Critz, W H Williams, C T Holladay, et al.
Experimental Hematology & Oncology|October 17, 2018
Early detection of transformation to BPDCN in a patient with MDSKamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, et al.
British Journal of Haematology|July 29, 2014
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemiaChristopher B Benton, Deborah A Thomas, Hui Yang, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
American Journal of Hematology|May 2, 2020
Thirty-three years later: Two distinct cases of acute lymphoblastic leukemia in one patientMarisa J L Aitken, Christopher B Benton, Feng Wang, et al.
Leukemia|July 29, 2017
Influence of IDH on FLT3-ITD status in newly diagnosed AMLP Boddu, K Takahashi, N Pemmaraju, et al.
Acta Haematologica|May 22, 2019
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell TransplantationZhihong Zeng, Wenbin Liu, Christopher B Benton, et al.
Annals of Tropical Medicine and Parasitology|June 26, 2002
APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis ControlM Homeida, E Braide, E Elhassan, et al.
The Journal of Investigative Dermatology|March 12, 2002
PARP determines the mode of cell death in skin fibroblasts, but not keratinocytes, exposed to sulfur mustardD S Rosenthal, C M Simbulan-Rosenthal, W F Liu, et al.
Leukemia & Lymphoma|September 17, 2013
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutationsChristopher B Benton, Farhad Ravandi, Michael Andreeff, et al.
Biochimica Et Biophysica Acta|December 26, 2015
Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cellsPeter P Ruvolo, Vivian R Ruvolo, Christopher B Benton, et al.
Urology|December 22, 1999
Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniquesF A Critz, W H Williams, C T Holladay, et al.
Experimental Hematology & Oncology|October 17, 2018
Early detection of transformation to BPDCN in a patient with MDSKamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, et al.
British Journal of Haematology|July 29, 2014
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemiaChristopher B Benton, Deborah A Thomas, Hui Yang, et al.
Pageof 7